Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
August 14, 2023 07:30 ET
|
Zevra Therapeutics
Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million...
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
August 07, 2023 16:45 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) ("Zevra" or “the Company"), a rare disease company melding science, data, and patient need to create...
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
August 02, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference
July 19, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
June 13, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
May 10, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
May 09, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
May 03, 2023 07:30 ET
|
Zevra Therapeutics
Zevra plans to expand KP1077 clinical program to address multiple rare sleep disorders with trials initiating in 2023 CELEBRATION, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc....
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy
April 17, 2023 16:05 ET
|
Zevra Therapeutics
Glass Lewis Recommends a Vote “FOR” Zevra’s Three Nominees Both ISS and Glass Lewis Recommend Shareholders DO NOT Vote “FOR” Any of the Mangless Nominees Zevra Urges Shareholders to Vote on the...
Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
April 04, 2023 07:30 ET
|
Zevra Therapeutics
Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or...